Stempeutics receives EU orphan drug designation for novel stem cell drug – Business Standard
Livemint |
Stempeutics receives EU orphan drug designation for novel stem cell drug
Business Standard The European Medicines Agency (EMA) has granted orphan drug designation (ODD) for Stempeutics Research's novel stem cell drug Stempeucel used in the treatment of thromboangiitis obliterans. The Bangalore-based Stempeutics Research is a group … Stempeutics eyes late-stage trial waiver for stem–cell drug Stempeutics' stem cell drug, Stempeucel receives European Orphan Drug … Stempeutics receives ODD in the European Union for its novel stem cell drug … |
